Verona Pharma plc Verona Pharma To Announce Interim Results For Six Months Ended June 30, 2017 And Provide Clinical Developme...

 
TIDMVRP 
 
 
   LONDON, Aug. 02, 2017 (GLOBE NEWSWIRE) -- Verona Pharma plc (AIM:VRP) 
(NASDAQ:VRNA) ("Verona Pharma"), a clinical-stage biopharmaceutical 
company focused on developing and commercializing innovative therapies 
for respiratory diseases, announces today that it will report its 
interim results for the six months ended June 30, 2017 on Tuesday, 
August 8, 2017. 
 
   Verona Pharma will host an investment community conference call at 8:00 
a.m. Eastern Daylight Time (1:00 pm British Summer Time) on August 8, 
2017 to discuss the interim financial results and provide a clinical 
development update. 
 
   Analysts and investors may participate in the conference call by 
utilizing the conference ID: 4729485 and dialing the following numbers: 
 
 
   -- [phone] or [phone] for callers in the United States 
 
   -- 0800 279 4841 or 44(0)20 3427 1905 for callers in the United Kingdom 
 
   -- 0800 589 2674 or 49(0)69 2222 10624 for calls in Germany 
 
 
   Those interested in listening to the conference call live via the 
internet may do so by visiting the "Investors" page of Verona Pharma's 
website at www.veronapharma.com and clicking on the webcast link. 
 
   A webcast replay of the conference call [audio] will be available on the 
"Investors" page of Verona Pharma's website at www.veronapharma.com. 
 
   About Verona Pharma plc 
 
   Verona Pharma is a clinical-stage biopharmaceutical company focused on 
developing and commercializing innovative therapies for the treatment of 
respiratory diseases with significant unmet medical needs. 
 
   Verona Pharma's product candidate, RPL554, is a first-in-class, inhaled, 
dual inhibitor of the enzymes phosphodiesterase 3 and 4 that acts as 
both a bronchodilator and an anti-inflammatory agent in a single 
compound. Verona Pharma is developing RPL554 for the treatment of 
chronic obstructive pulmonary disease (COPD) and cystic fibrosis (CF), 
and potentially asthma. 
 
   For further information, please contact: 
 
 
 
 
Verona Pharma plc                              Tel: [phone] 
Jan-Anders Karlsson, Chief Executive Officer   [e-mail] 
 
N+1 Singer (Nominated Adviser and UK Broker)   Tel: [phone] 
Aubrey Powell / James White / Alex 
Laughton-Scott 
 
FTI Consulting (UK Media and Investor          Tel: [phone] 
enquiries) 
Simon Conway / Stephanie Cuthbert /            [e-mail] 
 Natalie Garland-Collins 
 
ICR, Inc. (US Media and Investor enquiries) 
James Heins                                    Tel: [phone] 
                                               [e-mail] 
Stephanie Carrington                           Tel. [phone] 
                                               [e-mail] 
 
 
 
   This announcement is distributed by Nasdaq Corporate Solutions on behalf 
of Nasdaq Corporate Solutions clients. 
 
   The issuer of this announcement warrants that they are solely 
responsible for the content, accuracy and originality of the information 
contained therein. 
 
   Source: Verona Pharma plc via Globenewswire 
 
 
  http://www.veronapharma.com/ 
 

(END) Dow Jones Newswires

August 02, 2017 11:00 ET (15:00 GMT)

Copyright (c) 2017 Dow Jones & Company, Inc.